All In MedTech

FDA Clearance Tracker · P170030

ORSIRO Sirolimus Eluting Coronary Stent System

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Feb 22, 2019 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Feb 22, 2019

Approved

Time to decision

513 days

Received Sep 27, 2017. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P170030
Device name
ORSIRO Sirolimus Eluting Coronary Stent System
Applicant
Biotronik AG
Applicant location
BüLach
Received
Sep 27, 2017
Decided
Feb 22, 2019
Decision
Approved
Supplements
63 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code NIQ

FDA's approval statement

As written in FDA's record.

Approval of the Orsiro Sirolimus Eluting Coronary Stent System. This device is indicated for improving coronary luminal diameter in patients, including those with diabetes mellitus, with symptomatic heart disease, stable angina, unstable angina, non-ST elevation myocardial infarction or documented silent ischemia due to atherosclerotic lesions in the native coronary arteries with a reference vessel diameter of 2.25 mm to 4.0 mm and a lesion length of < 36 mm.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code NIQ. The earliest in FDA's data is P020026, decided Apr 24, 2003.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Biotronik AG

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.